-
01:24:19 PM

ALLR Stock News

09/14/23 9:25 AM
Nasdaq : ALLR
clinical triallow float
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology
CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Allarity Therapeutics (NASDAQ:ALLR) is a biotechnology company focused on realizing true personalized cancer care by developing targeted cancer therapies coupled with companion diagnostics. The company's unique approach involves utilizing its
RHEA-AI
positive
07/31/23 6:00 AM
Nasdaq : ALLR
clinical triallow float
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics for personalized cancer care, and Detsamma Investments Pty. Ltd.
RHEA-AI
neutral
07/05/23 9:45 AM
Nasdaq : ALLR
clinical triallow float
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
Boston , MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics for personalized cancer care, today announced initial results
RHEA-AI
positive